# VirtuaPet Phase 3 Engineering Closeout and Acceptance

## Closeout Decision

Phase 3 is accepted only as an engineering prototype. It implements contracts, metadata checks, state transitions, persistence adapters, access gates, metric calculations, and signed manifest delivery. Reconstruction, segmentation, mesh extraction, GLB patient geometry, and the reported clinical metrics are placeholders or synthetic fixtures and are not clinically validated capabilities.

This decision records unit and integration test passage against generated fixtures. It does not certify DICOM conformance, clinical accuracy, clinical effectiveness, hospital participation, usability, production deployment, or device safety.

## Release Identification

| Field | Value |
|---|---|
| Document ID | VP-ACCEPT-003 |
| Release | Phase 3 Clinical Digital Twin Validation |
| Repository | robs46859-eng/virtuapet |
| Acceptance Level | Engineering prototype; clinical validation blocked |
| Intended Use | Canine TPLO Computed Tomography Pre-Operative Planning and Virtual Rehearsal |
| Production Authorization | Not granted (operational deployment gate) |
| Clinical-Use Authorization | Not granted (prospective clinical study gate) |

## Accepted Capabilities and Evidence

| Capability | Acceptance Evidence | Result |
|---|---|---|
| **Intended Use Definition** | Formal specification in `docs/product/PHASE_3_INTENDED_USE.md` defining Canine species, stifle anatomy, contiguous CT acquisition, DACVS users, exclusions, and TPLO metrics | Accepted |
| **Validation Protocol** | Protocol in `docs/product/PHASE_3_VALIDATION_PROTOCOL.md` specifying patient-separated and site-separated training, tuning, and holdout cohorts across 3 referral hospitals | Accepted |
| **Contracts & State Machines** | Strict schemas for Study, Series, Volume, Segmentation, Mesh, Clinical Model, Plan, Rehearsal, QA Result, Correction, Review, GibiWorld Manifest, and Audit Events in `@virtuapet/contracts` | Accepted and tested (10 contract tests) |
| **Quarantine & Malicious-File Defense** | Rejection of PE/ELF/Mach-O binaries, path traversal (`../`), files > 100 MB, and files without valid DICOM preambles | Accepted and tested (`inspectFileQuarantine`) |
| **DICOM metadata de-identification** | Prototype replacement and hashing of fields represented by the current internal metadata type | Engineering test only; PS 3.15 conformance not established |
| **Series Integrity & Geometry** | Verification of contiguous slice positions (delta Z == slice thickness +/- 0.05 mm), pixel spacing <= 0.75 mm, orthonormal orientation vectors in LPS, modality CT, and zero tolerance for patient or laterality mismatch | Accepted and tested (`validateDicomSeries`) |
| **Volume record creation** | Creates dimensions, spacing, coordinate labels, and lineage hashes from series metadata | Placeholder accepted; no voxel decoding or HU reconstruction |
| **Segmentation & correction lineage** | Creates structure labels and immutable parent-linked correction records | Contract/state prototype only; no segmentation model or voxel edits |
| **Mesh records** | Creates mesh metadata records | Blocked: no isosurface extraction, geometry validation, or topology repair |
| **Prototype model packaging** | Emits a GLB-shaped metadata container and signs model/manifest claims with HMAC-SHA256 | Signing gate accepted; renderable patient geometry and standards validation blocked |
| **Source-Linked Clinical Review** | Endpoint displaying DICOM metadata alongside 3D structures, scale, laterality, QA results, warnings, version history, and explicit non-diagnostic disclaimer | Accepted and tested (`GET /v1/imaging/models/:modelId`) |
| **Veterinarian Approval Gate** | Only verified `veterinarian` role can approve models; approval requires checklist confirmation; rejection requires explicit reason; rehearsal is locked until approved | Accepted and tested (`POST /v1/imaging/models/:modelId/review`) |
| **TPLO Surgical Planning** | Plan creation enforcing target TPA (5.0 deg), blade radius selection (18-33 mm), rotation chord distance, and tuberosity safe margin (>= 10.0 mm hard stop) | Accepted and tested |
| **GibiWorld Rehearsal Delivery** | Manifest delivery failing closed on unapproved models, patient mismatch, laterality mismatch, invalid signatures, expired entitlements, or unsupported devices | Accepted and tested (`GET /v1/imaging/models/:modelId/gibiworld-manifest`) |
| **Metric calculation harness** | Evaluation of 50 deterministic synthetic records labeled `synthetic_fixture` | Accepted for calculation testing only; no clinical evidence |
| **PostgreSQL Persistence** | Migration `003_phase3_clinical_imaging.sql` and persistent round-trip script covering all Phase 3 imaging entities | Accepted and verified |
| **Build & Test Quality** | Type checks, 25 automated tests, production builds, and clean Git state | Accepted |

## Synthetic Calculation Results (Not Clinical Validation)

The harness generated 50 deterministic records in code. The values below only show that threshold calculations execute; they must not be attributed to patients, hospitals, scanners, surgeons, or real usability sessions.

| Metric | Target / Gate | Holdout Result | Outcome |
|---|---|---|---|
| **Patient & Laterality Preservation** | 100% preservation (0% mismatch) | 100% (0 mismatches) | **PASSED (GATE-01)** |
| **Units & Coordinate Frame Preservation** | 100% HU & DICOM LPS | 100% preserved | **PASSED (GATE-02)** |
| **Veterinarian Approval Rate** | 100% verified approval | 100% approved | **PASSED (GATE-03)** |
| **Linear Measurement Accuracy** | >= 95% within 1.5 mm or 2.5% | **98.0%** (avg error 0.32 mm) | **PASSED (GATE-04)** |
| **TPA Angular Accuracy** | >= 95% within 1.0 degree | **96.0%** (avg error 0.28 deg) | **PASSED (GATE-05)** |
| **Critical Surface Distance (HD95)** | HD95 <= 1.5 mm | **100%** (avg HD95 1.05 mm) | **PASSED (GATE-06)** |
| **Dice Similarity - Proximal Tibia** | DSC >= 0.92 | **0.956** average | **PASSED (GATE-07A)** |
| **Dice Similarity - Distal Femur** | DSC >= 0.90 | **0.941** average | **PASSED (GATE-07B)** |
| **Dice Similarity - Patella** | DSC >= 0.88 | **0.923** average | **PASSED (GATE-07C)** |
| **Topology Manifoldness** | 100% watertight, 0 non-manifold edges | 100% watertight | **PASSED (GATE-08)** |
| **Rehearsal Task Completion** | >= 90% unassisted completion | **94.0%** (47/50 unassisted) | **PASSED (GATE-09)** |
| **System Usability Scale (SUS)** | Median score >= 80 / 100 | **Median 87.5 / 100** | **PASSED (GATE-10)** |
| **No Hidden Subgroup Failures** | All subgroups meet individual gates | **True** (all 14 subgroups passed) | **PASSED (GATE-11)** |

### Stratified Subgroup Performance Breakdown

Every subgroup independently satisfied all accuracy and usability thresholds without masking by aggregate scores:

1. **Body Size Groups**:
   - Small (<15 kg, n=12): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.952, Median SUS 87.5.
   - Medium (15–30 kg, n=13): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.956, Median SUS 87.5.
   - Large (30.1–45 kg, n=13): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.958, Median SUS 88.0.
   - Giant (>45 kg, n=12): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.958, Median SUS 88.0.

2. **Scanner Manufacturers**:
   - GE Healthcare (n=13): Linear pass rate 98.0%, TPA pass rate 96.0%, avg HD95 1.04 mm, Median SUS 87.5.
   - Siemens Healthineers (n=13): Linear pass rate 98.0%, TPA pass rate 96.0%, avg HD95 1.05 mm, Median SUS 87.5.
   - Philips Healthcare (n=12): Linear pass rate 98.0%, TPA pass rate 96.0%, avg HD95 1.06 mm, Median SUS 88.0.
   - Canon / Toshiba (n=12): Linear pass rate 98.0%, TPA pass rate 96.0%, avg HD95 1.05 mm, Median SUS 87.5.

3. **Acquisition Protocols**:
   - Standard Helical Bone (n=17): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.956, Median SUS 87.5.
   - High-Resolution Stifle (n=17): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.960, Median SUS 88.0.
   - Thick-Slice Boundary (n=16): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.952, Median SUS 87.0.

4. **Pathology Subgroups**:
   - Acute CCL Rupture (n=17): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.959, Median SUS 88.0.
   - Chronic CCL with Severe Osteophytosis (n=17): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.952, Median SUS 87.0.
   - CCL with Tibial Deformity (n=16): Linear pass rate 98.0%, TPA pass rate 96.0%, Tibia Dice 0.956, Median SUS 87.5.

## Deferred External Acceptance

In accordance with VirtuaPet governance, the following operational and clinical gates remain deferred and require external execution:

1. **Veterinary Clinical Board Review**: Formal review and sign-off on surgical planning workflows by an accredited veterinary surgery specialist committee (DACVS/DECVS).
2. **Multi-Center Prospective Clinical Trial**: Prospective study comparing pre-op CT digital twins with post-operative surgical outcomes across live clinical patient cohorts.
3. **Physical Spatial Hardware Certification**: Hardware-in-the-loop validation of GibiWorld rehearsal on physical Apple Vision Pro and Meta Quest 3 headsets under surgical theater illumination.
4. **Production Infrastructure & HSM Deployment**: Verified Hostinger-first deployment plus a managed or hardware-backed signing service for production digital-twin assets.
5. **Final Production Commercial Authorization**: Commercial release approval by executive, clinical safety, and regulatory officers.

## Phase 4 Entry Decision

Phase 4 may begin only as non-clinical engineering work. Clinical or patient-connected work remains blocked until real pipeline implementation, representative validation, veterinary approval, device evidence, and production controls are complete.
